James C. Burnett
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
James C. Burnett has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Anfal S. Aljahdali
Department of Pharmaceutical Chemistry, Faculty of Pharmacy, King Abdulaziz University, Saudi Arabia
1 shared publication Donald J. Abraham
Virginia Commonwealth University, Richmond, VA, USA
1 shared publication- Elizabeth R. Sharlow
Department of Pharmacology, University of Virginia, Charlottesville, VA, USA
1 shared publication - Ettore J. Rastelli
Department of Chemistry, University of Houston , Houston, Texas 77204-5003, United States
1 shared publication - Isabella K. Blanco
Department of Pharmacology, University of Virginia, Charlottesville, USA
1 shared publication - John Lazo
Pharmacology, University of Virginia, United States
1 shared publication
Latest Publications
- 29 April 2021
- Published by Wiley
- p. 1-31
Therapeutic Strategies for the Treatment of Sickle Cell Disease
- 29 April 2021
- Published by Wiley
- p. 1-31
Therapeutic Strategies for the Treatment of Sickle Cell Disease
- 6 February 2019
- Published by Royal Society of Chemistry (RSC) in Organic & Biomolecular Chemistry
- Vol. 17 (9) , 2448-2466
In-flow photooxygenation of aminothienopyridinones generates iminopyridinedione PTP4A3 phosphatase inhibitors
A continuous flow photooxygenation of 7-aminothieno[3,2-c]pyridin-4(5H)-ones to produce 7-iminothieno[3,2-c]pyridine-4,6(5H,7H)-diones has been developed, utilizing ambient air as the sole reactant. N-H Imines are formed as the major products, and excellent functional group tolerance and conversion on gram-scale without the need for chromatographic purification allow for facile late-stage diversification of the aminothienopyridinone scaffold. Several analogs exhibit potent in vitro inhibition of the cancer-associated protein tyrosine phosphatase PTP4A3, and the SAR supports an exploratory docking model.
- 6 February 2019
- Published by Royal Society of Chemistry (RSC) in Organic & Biomolecular Chemistry
- Vol. 17 (9) , 2448-2466
In-flow photooxygenation of aminothienopyridinones generates iminopyridinedione PTP4A3 phosphatase inhibitors
A continuous flow photooxygenation of 7-aminothieno[3,2-c]pyridin-4(5H)-ones to produce 7-iminothieno[3,2-c]pyridine-4,6(5H,7H)-diones has been developed, utilizing ambient air as the sole reactant. N-H Imines are formed as the major products, and excellent functional group tolerance and conversion on gram-scale without the need for chromatographic purification allow for facile late-stage diversification of the aminothienopyridinone scaffold. Several analogs exhibit potent in vitro inhibition of the cancer-associated protein tyrosine phosphatase PTP4A3, and the SAR supports an exploratory docking model.